Check out Pro
Top CompaniesRecent TradesCluster BuysSectorsBlog
Join the Insiderviz Pro waitlist
ALPINE IMMUNE SCIENCES, INC. (ALPN)
Healthcare
Biotechnology
DATE
INSIDER
COMPANY
OWNED SHARES
SHARES TRADED
PRICE
NET TOTAL
SELL
25 Jan 2024
Rickey James Paul
See Remarks, Officer
ALPINE IMMUNE SCIENCES, INC.
(ALPN)
0-100%
118,000
$23.31
$2,751,021.80
SELL
28 Dec 2023
GOLD MITCHELL
Executive Chairman and CEO, Director, Officer
ALPINE IMMUNE SCIENCES, INC.
(ALPN)
0-100%
1,016
$20.04
$20,361.96
SELL
27 Dec 2023
ORBIMED ADVISORS LLC
Director
ALPINE IMMUNE SCIENCES, INC.
(ALPN)
3,466,613-30%
1,546,347
$18.54
$28,671,732.00
SELL
27 Dec 2023
Thompson Peter A.
Director
ALPINE IMMUNE SCIENCES, INC.
(ALPN)
3,466,613-30%
1,546,347
$18.54
$28,671,732.00
SELL
22 Dec 2023
GOLD MITCHELL
Executive Chairman and CEO, Director, Officer
ALPINE IMMUNE SCIENCES, INC.
(ALPN)
0-100%
91,884
$20.25
$1,860,528.50
SELL
19 Dec 2023
GOLD MITCHELL
Executive Chairman and CEO, Director, Officer
ALPINE IMMUNE SCIENCES, INC.
(ALPN)
0-100%
2,402
$20.01
$48,063.78
SELL
19 Dec 2023
Rickey James Paul
See Remarks, Officer
ALPINE IMMUNE SCIENCES, INC.
(ALPN)
0-100%
15,213
$19.21
$292,221.97
SELL
14 Dec 2023
Rickey James Paul
See Remarks, Officer
ALPINE IMMUNE SCIENCES, INC.
(ALPN)
0-100%
58,787
$19.07
$1,120,992.10
SELL
6 Nov 2023
Rickey James Paul
See Remarks, Officer
ALPINE IMMUNE SCIENCES, INC.
(ALPN)
0-100%
18,003
$16.03
$288,553.88
BUY
11 Feb 2022
Frazier Life Sciences VIII, L.P.
10% Owner
ALPINE IMMUNE SCIENCES, INC.
(ALPN)
1,484,115+8%
112,665
$7.10
$799,989.06
SELL
31 Dec 2021
Rickey James Paul
Senior VP and CFO, Officer
ALPINE IMMUNE SCIENCES, INC.
(ALPN)
7,014-70%
17,013
$13.92
$236,756.31
BUY
23 Sep 2021
CONWAY ROBERT E
Director
ALPINE IMMUNE SCIENCES, INC.
(ALPN)
50,000+42%
15,000
$10.08
$151,153.50
BUY
23 Sep 2021
Peetz Christopher
Director
ALPINE IMMUNE SCIENCES, INC.
(ALPN)
1,900+100%
1,900
$10.17
$19,323.00
BUY
21 Sep 2021
CONWAY ROBERT E
Director
ALPINE IMMUNE SCIENCES, INC.
(ALPN)
35,000+40%
10,000
$9.80
$97,966.00
SELL
17 Sep 2021
Venkatesan Jay
Director, 10% Owner
ALPINE IMMUNE SCIENCES, INC.
(ALPN)
2,600,980-13%
400,000
$9.40
$3,759,999.80
BUY
17 Sep 2021
Cui Xiangmin
Director, 10% Owner
ALPINE IMMUNE SCIENCES, INC.
(ALPN)
4,708,288+48%
1,542,553
$9.40
$14,499,998.00
BUY
17 Sep 2021
ORBIMED ADVISORS LLC
Director, 10% Owner
ALPINE IMMUNE SCIENCES, INC.
(ALPN)
3,656,061+38%
1,010,637
$9.40
$9,499,987.00
BUY
17 Sep 2021
Decheng Capital China Life Sciences USD Fund III, L.P.
10% Owner
ALPINE IMMUNE SCIENCES, INC.
(ALPN)
4,708,288+48%
1,542,553
$9.40
$14,499,998.00
BUY
17 Sep 2021
Thompson Peter A.
Director, 10% Owner
ALPINE IMMUNE SCIENCES, INC.
(ALPN)
3,656,061+38%
1,010,637
$9.40
$9,499,987.00
SELL
17 Sep 2021
Alpine ImmunoSciences, L.P.
10% Owner
ALPINE IMMUNE SCIENCES, INC.
(ALPN)
2,600,980-13%
400,000
$9.40
$3,759,999.80
SELL
17 Sep 2021
GOLD MITCHELL
Executive Chairman and CEO, Director, Officer, 10% Owner
ALPINE IMMUNE SCIENCES, INC.
(ALPN)
2,600,980-14%
445,262
$9.46
$4,212,963.50
SELL
15 Sep 2021
GOLD MITCHELL
Executive Chairman and CEO, Director, Officer, 10% Owner
ALPINE IMMUNE SCIENCES, INC.
(ALPN)
154,649-6%
10,252
$10.00
$102,536.24
SELL
25 Jun 2021
GOLD MITCHELL
Executive Chairman and CEO, Director, Officer, 10% Owner
ALPINE IMMUNE SCIENCES, INC.
(ALPN)
164,901-7%
12,952
$10.01
$129,657.20
SELL
19 May 2021
GOLD MITCHELL
Executive Chairman and CEO, Director, Officer, 10% Owner
ALPINE IMMUNE SCIENCES, INC.
(ALPN)
177,853-22%
52,186
$15.03
$784,233.06
SELL
12 May 2021
GOLD MITCHELL
Executive Chairman and CEO, Director, Officer, 10% Owner
ALPINE IMMUNE SCIENCES, INC.
(ALPN)
230,039-7%
20,000
$11.60
$232,011.00
SELL
13 Apr 2021
GOLD MITCHELL
Executive Chairman and CEO, Director, Officer, 10% Owner
ALPINE IMMUNE SCIENCES, INC.
(ALPN)
250,039-7%
20,000
$10.30
$205,914.00
SELL
4 Mar 2021
GOLD MITCHELL
Executive Chairman and CEO, Director, Officer, 10% Owner
ALPINE IMMUNE SCIENCES, INC.
(ALPN)
270,039-6%
20,000
$13.00
$259,983.00
SELL
1 Feb 2021
GOLD MITCHELL
Executive Chairman and CEO, Director, Officer, 10% Owner
ALPINE IMMUNE SCIENCES, INC.
(ALPN)
290,039-6%
20,000
$12.30
$246,046.40
SELL
28 Dec 2020
ORBIMED ADVISORS LLC
Director, 10% Owner
ALPINE IMMUNE SCIENCES, INC.
(ALPN)
3,070,955-16%
600,000
$14.25
$8,550,000.00
SELL
28 Dec 2020
Thompson Peter A.
Director, 10% Owner
ALPINE IMMUNE SCIENCES, INC.
(ALPN)
3,070,955-16%
600,000
$14.25
$8,550,000.00
BUY
19 Nov 2020
CONWAY ROBERT E
Director
ALPINE IMMUNE SCIENCES, INC.
(ALPN)
25,000+66%
10,000
$8.03
$80,300.00
BUY
30 May 2019
Rickey James Paul
Senior VP and CFO, Officer
ALPINE IMMUNE SCIENCES, INC.
(ALPN)
10,000+100%
10,000
$4.95
$49,500.00
SELL
8 Feb 2019
TIGER MANAGEMENT L.L.C.
10% Owner
ALPINE IMMUNE SCIENCES, INC.
(ALPN)
137,728-15%
25,000
$5.85
$146,245.00
BUY
18 Jan 2019
Venkatesan Jay
Director, 10% Owner
ALPINE IMMUNE SCIENCES, INC.
(ALPN)
3,994,781+5%
190,875
$5.37
$1,024,998.75
BUY
18 Jan 2019
Frazier Life Sciences VIII, L.P.
10% Owner
ALPINE IMMUNE SCIENCES, INC.
(ALPN)
2,571,450+16%
372,439
$5.37
$1,999,997.40
BUY
18 Jan 2019
Thompson Peter A.
Director, 10% Owner
ALPINE IMMUNE SCIENCES, INC.
(ALPN)
3,670,955+11%
372,439
$5.37
$1,999,997.40
BUY
18 Jan 2019
ORBIMED ADVISORS LLC
Director, 10% Owner
ALPINE IMMUNE SCIENCES, INC.
(ALPN)
3,670,955+11%
372,439
$5.37
$1,999,997.40
BUY
18 Jan 2019
Alpine ImmunoSciences, L.P.
10% Owner
ALPINE IMMUNE SCIENCES, INC.
(ALPN)
3,994,781+5%
190,875
$5.37
$1,024,998.75
BUY
18 Jan 2019
GOLD MITCHELL
Executive Chairman and CEO, Director, Officer, 10% Owner
ALPINE IMMUNE SCIENCES, INC.
(ALPN)
3,994,781+5%
190,875
$5.37
$1,024,998.75
BUY
18 Jan 2019
Topper James N
Director, 10% Owner
ALPINE IMMUNE SCIENCES, INC.
(ALPN)
2,571,450+16%
372,439
$5.37
$1,999,997.40
BUY
20 Jun 2017
BVF PARTNERS L P/IL
10% Owner
Nivalis Therapeutics, Inc.
(NVLS)
1,109,258+0%
4,451.5
$9.00
$40,063.50
BUY
5 Jun 2017
BVF PARTNERS L P/IL
10% Owner
Nivalis Therapeutics, Inc.
(NVLS)
1,099,526+1%
18,162.5
$9.14
$166,068.94
BUY
30 May 2017
BVF PARTNERS L P/IL
10% Owner
Nivalis Therapeutics, Inc.
(NVLS)
1,060,139+1%
11,750
$9.07
$106,529.43
BUY
17 May 2017
BVF PARTNERS L P/IL
10% Owner
Nivalis Therapeutics, Inc.
(NVLS)
1,034,597+1%
19,714.5
$9.20
$181,318.86
BUY
9 May 2017
CONWAY ROBERT E
Director
Nivalis Therapeutics, Inc.
(NVLS)
45,000+2%
1,250
$9.36
$11,700.00
BUY
9 May 2017
BVF PARTNERS L P/IL
10% Owner
Nivalis Therapeutics, Inc.
(NVLS)
986,943+2%
27,258.5
$9.30
$253,429.34
BUY
8 May 2017
CONWAY ROBERT E
Director
Nivalis Therapeutics, Inc.
(NVLS)
60,000+6%
3,750
$9.12
$34,200.00
BUY
5 May 2017
CONWAY ROBERT E
Director
Nivalis Therapeutics, Inc.
(NVLS)
40,000+14%
5,000
$9.20
$46,000.00
BUY
5 May 2017
TROHA JANICE
Exec Vice President / COO, Officer
Nivalis Therapeutics, Inc.
(NVLS)
10,000+33%
2,500
$9.36
$23,400.00
BUY
4 May 2017
CONWAY ROBERT E
Director
Nivalis Therapeutics, Inc.
(NVLS)
20,000+14%
2,500
$9.04
$22,600.00
SELL
3 Jan 2017
Rodman David Malcom
Exec Vice President and CMO, Officer
Nivalis Therapeutics, Inc.
(NVLS)
11,368-12%
1,671.75
$9.08
$15,179.49
BUY
2 Dec 2016
Carruthers R Michael
Exec Vice President / CFO, Officer
Nivalis Therapeutics, Inc.
(NVLS)
24,000+33%
6,000
$8.38
$50,256.00
SELL
3 Oct 2016
Rodman David Malcom
Exec Vice President and CMO, Officer
Nivalis Therapeutics, Inc.
(NVLS)
12,236-10%
1,455
$31.84
$46,327.20
SELL
1 Jul 2016
Rodman David Malcom
Exec Vice President and CMO, Officer
Nivalis Therapeutics, Inc.
(NVLS)
12,105-10%
1,487.5
$18.64
$27,727.00
BUY
16 Jun 2016
Congleton Jon
President and CEO, Director, Officer
Nivalis Therapeutics, Inc.
(NVLS)
20,000+6%
1,250
$15.48
$19,344.50
BUY
24 Mar 2016
Congleton Jon
President and CEO, Director, Officer
Nivalis Therapeutics, Inc.
(NVLS)
15,000+9%
1,250
$16.87
$21,084.50
BUY
22 Mar 2016
Congleton Jon
President and CEO, Director, Officer
Nivalis Therapeutics, Inc.
(NVLS)
10,000+14%
1,250
$17.53
$21,907.50
Home
Top CompaniesForm ScreenerSectors
DisclaimersPrivacyTerms of Service
ContactBlogNewsletter